ImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024. In the quarter to June 2026, revenue grew 93.9%, EPS fell 120.0%, free cash flow grew 13.4% and total debt rose 57.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow IBRX
ImmunityBio, Inc. (IBRX) Beneish M-score
ImmunityBio, Inc.'s Beneish M-score for fiscal 2025 is 4.57; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | 4.57 | 4.71 |
| FY2022 | −0.13 | 2.17 |
| FY2021 | −2.30 | 0.65 |
| FY2020 | −2.95 | (40.80) |
| FY2019 | 37.85 | 34.03 |
| FY2018 | 3.82 | 7.88 |
| FY2017 | −4.07 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 2.35 | — | 2.16 | |
| Gross margin index | 1.01 | — | 0.53 | |
| Asset quality index | 0.91 | — | 0.37 | |
| Sales growth index | 7.68 | — | 6.85 | |
| Depreciation index | 1.89 | — | 0.22 | |
| SG&A index | 0.12 | — | −0.02 | |
| Total accruals to total assets | (0.09) | — | −0.43 | |
| Leverage index | 0.80 | — | −0.26 | |
| Beneish M-score | Flagged by the model | 4.57 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| SMMT Summit Therapeutics PLC compare | −5.0× |
| CORT Corcept Therapeutics Incorporated compare | −2.8× |
| TECH Bio-Techne Corp compare | −2.5× |
| BMRN BioMarin Pharmaceutical Inc. compare | −2.5× |
| KRYS Krystal Biotech, Inc. compare | −2.3× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 0.5× |
| IBRX ImmunityBio, Inc. | 4.6× |
| PCVX Vaxcyte, Inc. compare | — |
| KYMR Kymera Therapeutics, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI